S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:APTXAptinyx Stock Price, Forecast & News

$4.04
-0.05 (-1.22 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.98
Now: $4.04
$4.24
50-Day Range
$3.69
MA: $4.27
$4.99
52-Week Range
$1.60
Now: $4.04
$5.28
Volume115,683 shs
Average Volume340,509 shs
Market Capitalization$184.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Read More
Aptinyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
Phone847-871-0377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.67 million
Book Value$2.31 per share

Profitability

Net Income$-57,410,000.00
Net Margins-1,540.42%

Miscellaneous

EmployeesN/A
Market Cap$184.45 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableNot Optionable
$4.04
-0.05 (-1.22 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aptinyx (NASDAQ:APTX) Frequently Asked Questions

How has Aptinyx's stock been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTX stock has increased by 66.3% and is now trading at $4.04.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Aptinyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx
.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx
.

How can I listen to Aptinyx's earnings call?

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) posted its earnings results on Thursday, May, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The business earned $0.82 million during the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%.
View Aptinyx's earnings history
.

What price target have analysts set for APTX?

6 brokerages have issued 1-year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $15.00. On average, they expect Aptinyx's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price.
View analysts' price targets for Aptinyx
.

Has Aptinyx been receiving favorable news coverage?

Media headlines about APTX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Aptinyx
.

Are investors shorting Aptinyx?

Aptinyx saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 246,700 shares, an increase of 24.3% from the January 31st total of 198,500 shares. Based on an average trading volume of 302,100 shares, the short-interest ratio is presently 0.8 days. Currently, 1.2% of the shares of the company are short sold.
View Aptinyx's Short Interest
.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), New York State Common Retirement Fund (0.05%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx
.

Which institutional investors are buying Aptinyx stock?

APTX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, New York State Common Retirement Fund, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx
.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $4.04.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $184.45 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

What is Aptinyx's official website?

The official website for Aptinyx is www.aptinyx.com.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.